Does a Common Mechanism Trigger Attacks in Episodic Ataxia Type 2?

2 型发作性共济失调是否有共同机制引发发作?

基本信息

  • 批准号:
    8835728
  • 负责人:
  • 金额:
    $ 4.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-21 至 2017-09-20
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Episodic ataxia type 2 (EA2) is a neurological disorder caused by mutations in the CACNA1A gene encoding for the pore forming α-1a subunit of the P/Q type voltage gated calcium channel (Cav2.1). EA2 patients exhibit episodic attacks of severe ataxia triggered by different stressors such as, caffeine and alcohol consumption and physical or emotional stress. Previous work in our lab has shown that the motor attacks in a rodent EA2 model, tottering, are due to an aberrant output from the cerebellum driven by erratic burst firing of Purkinje cells (PC). The tottering mouse is a well-established rodent model of EA2. They carry a spontaneous mutation in the CACNA1A gene rendering the Cav2.1 channel non-functional and exhibit motor attacks induced by stress, caffeine and alcohol similar to EA2 patients. Interestingly, all three triggers result in the same change in the firing pattern of PCs n these animals, suggesting a common converging mechanism. PCs are intrinsically active and in vivo exhibit tonic firing at 50 spikes per second. This firing pattern is partially governed by the tight coupling of Cav2.1 channels to the small conductance calcium activated potassium channels (SK2) that help regulate the intrinsic activity of these cells. It has been shown that blocking SK2 channels promotes burst firing of wild type PCs, whereas activating them in the cerebellum of tottering mice restores PC regularity and alleviates attacks induced by caffeine or stress. Give that the calcium current through Cav2.1 channels in tottering mice is already diminished and that SK2 channels are gated by Cav2.1 dependent calcium, a further reduction in SK2 activity could be the cause for the observed bursting of PCs during attacks. Indeed, preliminary data from our lab suggests that all three triggers converge on the modulation of SK2 activity. Interestingly, this modulation seems to be dependent on increases in norepinephrine (NE) levels in the cerebellum, a phenomenon known to occur in response to stress, caffeine and alcohol. Thus, our working hypothesis is that all three triggers functionally converge to reduce open probability of PCs SK2 channels via a NE dependent mechanism. My main goal in this proposal is to further delineate the mechanism driving the attacks in tottering mice by perturbing SK2 gating and asking how it will affect attacks. I plan to achieve this by combining electrophysiological techniques together with molecular biology and behavioral tests. This powerful approach will allow me to link molecular mechanisms, physiological function and behavior.


项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ariel Vitenzon其他文献

Ariel Vitenzon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 4.27万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 4.27万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 4.27万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 4.27万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 4.27万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 4.27万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 4.27万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 4.27万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 4.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了